<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03138525</url>
  </required_header>
  <id_info>
    <org_study_id>ML39789</org_study_id>
    <nct_id>NCT03138525</nct_id>
  </id_info>
  <brief_title>Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis</brief_title>
  <official_title>Immune Profiling During Ocrelizumab Treatment in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brigham and Women's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Brigham and Women's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess effects of B cell depletion on the immune system in
      patients with relapsing forms of multiple sclerosis (MS) treated with ocrelizumab. This will
      be done by collecting blood from patients starting treatment with ocrelizumab before the
      first infusion and before the infusions at 6 and 12 months. The effects on the immune system
      will be assessed by performing transcriptome profiling of immune cells, measuring serum
      levels of microRNAs, and analyzing serum autoantibody immune signatures using antigen arrays.
      In addition, blood will be collected once from a group of healthy individuals to serve as
      controls.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 20, 2017</start_date>
  <completion_date type="Anticipated">November 2019</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Monocyte Transcriptome Profiling</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in messenger ribonucleic acid (mRNA) expression</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Antigen microarrays</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in serum autoantibody immune signatures</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serum microRNA profiles</measure>
    <time_frame>12 months</time_frame>
    <description>Changes in serum microRNA expression</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Multiple Sclerosis</arm_group_label>
    <description>Subjects with multiple sclerosis (MS) initiating treatment with ocrelizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy</arm_group_label>
    <description>Healthy individuals serving as controls to the subjects with MS</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling (MS)</intervention_name>
    <description>Blood samples will be collected before initiation of Ocrelizumab treatment and after 6 and 12 months of treatment.</description>
    <arm_group_label>Multiple Sclerosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sampling (controls)</intervention_name>
    <description>Blood samples will be collected once at enrollment.</description>
    <arm_group_label>Healthy</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, and peripheral blood mononuclear cells.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with relapsing form of MS starting treatment with ocrelizumab at Partners MS
        Center
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with relapsing form of MS starting treatment with ocrelizumab at Partners MS
             Center

          -  Healthy controls

          -  Ability to understand and sign informed consent

        Exclusion Criteria - All subjects:

          -  Other concomitant autoimmune or inflammatory diseases

          -  Ongoing treatment with other immunomodulatory medications

          -  Previous treatment with rituximab, methotrexate, cyclophosphamide, mitoxantrone,
             mycophenolate mofetil, or alemtuzumab

          -  Pregnancy or lactation

          -  Hypersensitivity to ocrelizumab

        Exclusion Criteria - Healthy Controls:

          -  MS

          -  First-degree relatives with MS
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Howard L Weiner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Brigham and Women's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pia Kivisakk, MD, PhD</last_name>
    <phone>617-732-5588</phone>
    <email>MSSTUDIES@partners.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MS Study Line</last_name>
      <phone>617-732-5588</phone>
      <email>MSSTUDIES@partners.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 1, 2017</study_first_submitted>
  <study_first_submitted_qc>May 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Brigham and Women's Hospital</investigator_affiliation>
    <investigator_full_name>Howard L Weiner</investigator_full_name>
    <investigator_title>Director, Partners Multiple Sclerosis Center; Co-Director, Ann Romney Center for Neurologic Diseases</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

